PTPeter Torre

Peter Torre

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Peter Torre has a total of 46 co-authors. Here are the top co-authors by number of shared publications:

  • Howard J. Hoffman

    Epidemiology, Statistics, and Population Sciences Section, National Institute on Deafness and Other Communication Disorders National Institutes of Health Bethesda Maryland USA

    4 shared publications
  • Christopher Cox

    Department of Epidemiology, Johns Hopkins University Bloomberg School of Public Health, Baltimore, MD, United States

    3 shared publications
  • Gayle Springer

    Department of Epidemiology, Johns Hopkins University Bloomberg School of Public Health, Baltimore, MD, United States

    3 shared publications
  • Joseph B. Margolick

    Department of Molecular Microbiology and Immunology, Johns Hopkins University Bloomberg School of Public Health, Baltimore, MD, United States

    3 shared publications
  • Michael Plankey

    Department of Medicine, Division of Infectious Diseases, Georgetown University Medical Center, Washington, D.C., United States

    3 shared publications
  • Bret Zeldow

    Center for Biostatistics in AIDS Research, Harvard School of Public Health, Boston, MA

    2 shared publications

Latest Publications

  • Can Self-Reported Personal Audio System Volume Predict Actual Listening Levels in Young Adults?

    by Peter Torre, Mark B. Reed

    Background:Most young adults report using personal audio systems (PAS) with earphones as part of their daily activities. PAS exposure is intermittent and research examining the levels these young adults are listening to is increasing. On average, preferred listening levels are below what would be considered at risk in an occupational setting.Purpose:The purpose of this study was to evaluate how two questions predicted preferred listening level in young adults with normal hearing; specifically, whether these young adults could identify if they listen at a high level or not.Study Sample:One hundred and sixty young adults (111 women, 49 men) with normal hearing completed a questionnaire that had questions about PAS listening habits and then had preferred listening level assessed using a probe microphone system while listening to 1 hour of music through earphones.Data Collection and Analysis:Otoscopy, tympanometry, and pure-tone thresholds were completed in a randomly determined test ear. As part of the Risk Factors Survey, two closed-set questions were completed. First, “For a typical day, what is the most common volume used during this day?” with the following response options “Low,” “Medium/Comfortable,” “Loud,” or “Very Loud.” And second, “Do you listen to your personal music system at a volume where you…” with the following response options “Easily hear people,” “Have a little trouble hearing people,” “Have a lot of trouble hearing people,” or “Cannot hear people.” Using a probe microphone, chosen listening level (A-weighted, diffuse-field correction and a conversion to free-field equivalent [LDFeq]) was calculated over 1 hour while the participant listened to music with earphones. Sensitivity and specificity were determined to see how well young adults could identify themselves as listening at a high level (>85 dBA) or not. Linear regression analyses were performed to determine the amount of variance explained by the two survey questions as predictors of measured LDFeq.Results:Almost half of the participants reported a longest single use of a PAS as 85 dBA) while in a quiet background. The participants who do report listening at a high level, however, do well at self-reporting this risk behavior in survey questions.


  • Speech audiometry findings from HIV+ and HIV− adults in the MACS and WIHS longitudinal cohort studies

    by Peter Torre, Howard J. Hoffman, Gayle Springer, Christopher Cox, Mary A. Young, Joseph B. Margolick, Michael Plankey


    • 5 September 2016
      • Vol. 1  (1)
    Open Access

    Newborn Hearing Screenings in Human Immunodeficiency Virus-Exposed Uninfected Infants

    by P Torre, B Zeldow, Tj Yao, HJ Hoffman, Gk Siberry, Mu Purswani, T Frederick, Sa Spector, Pl Williams

    Perinatal HIV infection and congenital cytomegalovirus (CMV) infection may increase the risk for hearing loss. We examined 1,435 infants enrolled in the Surveillance Monitoring of ART Toxicities (SMARTT) study of the Pediatric HIV/AIDS Cohort Study (PHACS) network, a prospective study of the safety of in utero antiretroviral (ARV) exposures. We determined the proportion of perinatally HIV-exposed uninfected (HEU) newborns who were referred for additional hearing testing, and evaluated the association between in utero ARV exposures and newborn hearing screening results. Using a nested case-control design, we also examined congenital CMV infection in infants with and without screening referral. Congenital CMV infection was determined based on CMV DNA detection using a nested PCR assay in peripheral blood mononuclear cells obtained within 14 days of birth. Among the 1,435 infants (70% black, 31% Hispanic, 51% male), 45 (3.1%) did not pass the hearing screen and were referred for further hearing testing. Based on exact logistic regression models controlling for maternal use of tobacco and ototoxic medications, first trimester exposure to Tenofovir was associated with lower odds of a newborn hearing screening referral [adjusted odds ratio (aOR) = 0.41, 95% confidence interval (CI): 0.14-1.00]. Exposure to Atazanavir was linked to higher odds of newborn screening referral, although not attaining significance [aOR = 1.84, 95% CI: 0.92-3.56]. Maternal ARV use may have varying effects on newborn hearing screenings. These results highlight the importance for audiologists to be knowledgeable of in utero ARV exposures in HEU children because of the possibility of higher referrals in these children.


  • Hearing assessment data in HIV-infected and uninfected children of Cape Town, South Africa

    by Peter Torre, Alyssa Cook, Haley Elliott, Gouwa Dawood, Barbara Laughton

    Researchers are showing that the rate of hearing loss in children with perinatal HIV infection (PHIV) is higher than in HIV-unexposed, uninfected children. These data, however, have been collected mostly in the USA; extensive hearing data from low- and middle-income countries are lacking. The purpose of this study was to collect audiometric data in PHIV and HIV-uninfected children living in Cape Town, South Africa. Questionnaire data along with distortion product otoacoustic emissions (DPOAEs) and pure-tone testing were completed. Hearing loss was determined using the pure-tone thresholds defined as a pure-tone average (PTA) of 500, 1000, 2000, and 4000 Hz of >15 dB HL in the poorer ear. All data were compared between PHIV and HIV-uninfected children. Sixty-one (37 PHIV and 24 HIV-uninfected) children had hearing data. HIV status was not significantly associated with DPOAEs. The rate of conductive hearing loss was 11.5%; five PHIV and two HIV-uninfected children. The rate of any hearing loss was higher in PHIV children, but this difference was not statistically significant. PHIV children had a significantly higher mean PTA in the poorer ear than HIV-uninfected children. Conductive type of hearing loss was more common than sensorineural hearing loss. The underlying cause of hearing loss in the present study therefore remains unclear. Future research should include an examination of auditory neural function in an effort to determine the possible reason for differences in hearing.


  • Open Access

    Hearing Loss Among HIV-Seropositive and HIV-Seronegative Men and Women

    by Peter Torre, Howard J. Hoffman, Gayle Springer, Christopher Cox, Mary A. Young, Joseph B. Margolick, Michael Plankey

    The relationship between human immunodeficiency virus (HIV) infection and hearing loss in the era of highly active antiretroviral therapy (HAART) has not been extensively investigated. In one of the few studies to prospectively evaluate possible changes in hearing sensitivity in HIV-seropositive (HIV+) individuals, Schouten et al1 evaluated pure-tone averages (PTAs) in adults who began receiving zidovudine or didanosine, alone or in combination, from 1996 through 1999 with other antiretroviral therapy (ART) not specified. Low-frequency PTAs (500, 1000, and 2000 Hz) and high-frequency PTAs (4000, 8000, and 12 000 Hz) were calculated at baseline, 16 weeks, and 32 weeks. For the participants who had PTA data and returned at 32 weeks (n = 19), there were no significant changes in either high-frequency PTA (HPTA) or low-frequency PTA (LPTA), after accounting for age, noise exposure, CD4+ T-cell count, and viral load.


  • Distortion Product Otoacoustic Emission Data in Perinatally HIV-infected and HIV-exposed but Uninfected Children and Adolescents in the Pediatric HIV/AIDS Cohort Study

    by Peter Torre, Tzy-Jyun Yao, Bret Zeldow, Paige Williams, Howard J. Hoffman, George K. Siberry

    The effect of perinatal HIV infection and exposure on sub-clinical auditory function can be measured with distortion product otoacoustic emissions (DPOAEs). DPOAEs were obtained at 4 frequency bins (1, 2, 3 and 4 kHz) and categorized by a signal-to-noise ratio. HIV infection was not associated with poorer DPOAEs. Among HIV-infected children, HIV viral load ≥400 copies/mL had significantly lower odds of better DPOAEs.


  • Cochlear Function Among HIV-Seropositive and HIV-Seronegative Men and Women

    by Peter Iii Torre, Howard J. Hoffman, Gayle Springer, Christopher Cox, Mary Young, Joseph B. Margolick, Michael Plankey

    Objectives: There is limited research about cochlear function in adults who are human immunodeficiency virus (HIV) positive (+). The aim of the present study was to collect measures of cochlear function in a large sample of adults with, or at risk for, HIV infection, to evaluate associations between HIV status, HIV treatment, and cochlear function. Design: Distortion product otoacoustic emissions (DPOAEs) were used to evaluate cochlear function in 506 participants; 329 men, 150 of whom were HIV+, and 177 women, 136 of whom were HIV+. DPOAEs were measured at frequencies 1000, 2000, 3000, 4000, and 6000 Hz. A DPOAE nonresponse (NR) was defined as an absolute DPOAE level less than −15 dB SPL or a difference between the absolute DPOAE level and the background noise level less than 6 dB. The total number of NRs was calculated for each ear. The associations of demographic variables, HIV status, and HIV treatment with number of NRs were evaluated with univariate and multivariate ordinal regression models. Results: There was a statistically significant increase in the odds of higher numbers of NRs with age, being male, and being non-Black, but not with HIV status. Among HIV+ participants, there were no statistically significant associations of the HIV disease status or treatment variables with higher number of NRs. Conclusion: The authors found no evidence of impaired cochlear function by HIV disease status or highly active antiretroviral therapy–treated HIV infection in this cross-sectional study.


  • Hearing Loss in Perinatally HIV-infected and HIV-exposed but Uninfected Children and Adolescents

    by Peter Torre, Bret Zeldow, Howard J. Hoffman, Ashley Buchanan, George K. Siberry, Mabel Rice, Patricia A. Sirois, Paige L. Williams

    Background: Little is known about hearing loss in children with HIV infection (HIV+). We examined the prevalence of hearing loss in perinatally HIV+ and HIV-exposed but uninfected (HEU) children, compared these with the percentage with hearing loss in the general population and evaluated possible risk factors for hearing loss in HIV+ and HEU children. Methods: Audiometric examinations were completed in children who met any prespecified criteria for possible hearing loss. The hearing examination consisted of a tympanogram in each ear and pure-tone air-conduction threshold testing from 500 through 4000 Hz. Hearing loss was defined as the pure-tone average over these frequencies ≥20 dB hearing level. The associations of demographic variables, parent/caregiver, HIV disease and HIV treatment with hearing loss were evaluated with univariate and multivariable logistic regression models. Results: Hearing testing was completed in 231 children (145 HIV+ and 86 HEU). Hearing loss occurred in 20.0% of HIV+ children and 10.5% of HEU children. After adjusting for caregiver education level, HIV infection was associated with increased odds of hearing loss (adjusted odds ratio = 2.13, 95% confidence interval: 0.95–4.76, P = 0.07). Among HIV+ children, those with a Centers for Disease Control and Prevention class C diagnosis had over twice the odds of hearing loss (adjusted odds ratio = 2.47, 95% confidence interval: 1.04–5.87, P = 0.04). The prevalence of hearing loss was higher in both HIV+ and HEU children compared with National Health and Nutrition Examination Survey III children. Conclusions: Hearing loss was more common in both HIV+ and HEU children than in children from a US population sample. More advanced HIV illness increased the risk of hearing loss in HIV+ children.